BioSpace News Archive

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 6th Annual Guggenheim Biotechnology Conference being held at the St. Regis in New York, New York.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its fourth quarter 2023 financial results on Thursday, February 8, 2024, at 8:00 a.m. ET.

Myeloid Therapeutics, Inc., a clinical stage oncology company, has appointed Robert Hofmeister, Ph.D., as Chief Scientific Officer.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR).

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that four abstracts highlighting ultra-low-field imaging data will be presented at the 2024 International Stroke Conference (ISC), held from February 7–9 in Phoenix.

Proniras Corporation (“Proniras”) today announced the successful completion of a $4.65 million funding round, marking a significant milestone in its ongoing Series B financing, which aims to secure up to $9 million.

Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference, taking place February 7-8, 2024, in New York, New York.

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”) today announced the signing of an exclusive long-term license agreement with BIRAD, a research & development company of Bar-Ilan University, to use the joint patent it has with BIRAD for innovative cocaine treatment.

Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy using a minimally invasive (MIS) surgical technique.

Cortex announced today the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in late October 2023.